Shares of Arsanis Inc (NASDAQ:ASNS) reached a new 52-week low on Monday . The company traded as low as $2.35 and last traded at $2.44, with a volume of 1071 shares. The stock had previously closed at $2.50.
ASNS has been the subject of a number of analyst reports. Zacks Investment Research upgraded shares of Arsanis from a “hold” rating to a “buy” rating and set a $4.00 target price for the company in a report on Tuesday, July 10th. Cantor Fitzgerald reissued a “buy” rating and issued a $26.00 price target on shares of Arsanis in a research note on Thursday, June 28th. Cowen downgraded shares of Arsanis from an “outperform” rating to a “market perform” rating in a research note on Monday, July 2nd. ValuEngine raised shares of Arsanis from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Finally, Citigroup downgraded shares of Arsanis from a “buy” rating to a “neutral” rating in a research note on Monday, July 9th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $20.00.
The company has a market capitalization of $36.17 million and a PE ratio of -0.15. The company has a debt-to-equity ratio of 0.20, a quick ratio of 7.38 and a current ratio of 7.38.
A number of hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. raised its stake in Arsanis by 6.4% in the first quarter. JPMorgan Chase & Co. now owns 247,415 shares of the company’s stock worth $5,663,000 after buying an additional 14,819 shares in the last quarter. BlackRock Inc. bought a new position in Arsanis in the first quarter worth about $4,029,000. First Eagle Investment Management LLC bought a new position in Arsanis in the first quarter worth about $2,847,000. Northern Trust Corp bought a new position in Arsanis in the first quarter worth about $735,000. Finally, Millennium Management LLC bought a new position in Arsanis in the fourth quarter worth about $299,000. 71.60% of the stock is owned by institutional investors.
Arsanis, Inc, a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.
Read More: Book Value Per Share – BVPS
Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.